MAP Pharma Raises $50 Million

MAP Pharmaceuticals Inc., a Mountain View, Calif.-based developer of inhaled drug products for respiratory and CNS diseases, has raised has raised $50 million in Series D funding. D.E. Shaw Group was joined by return backers Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital and Skyline Ventures. MAP Pharma has raised around $107 million in total VC funding since its 2003 formation. It also recently completed Phase II clinical trials for its two lead programs for pediatric asthma and migraine.